Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study - Ketteler, M.; Martin, K. J.; Cozzolino, M.; Goldsmith, D.; Sharma, A.; Khan, S.; Dumas, E.; Amdahl, M.; Marx, S.; Audhya, P. (Nephrology, dialysis, transplantation, 2012)
Keywords: Adult; Aged; Aged, 80 and over; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Biological and medical sciences; Bone Density Conservation Agents - adverse effects; Bone Density Conservation Agents - therapeutic use; Calcimimetic Agents - adverse effects; Calcimimetic Agents - therapeutic use; Cinacalcet Hydrochloride; Cohort Studies; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emergency and intensive care: renal failure. Dialysis management; Ergocalciferols - adverse effects; Ergocalciferols - therapeutic use; Female; General and cellular metabolism. Vitamins; Humans; Hyperparathyroidism, Secondary - drug therapy; Intensive care medicine; Kidney Diseases - therapy; Male; Medical sciences; Middle Aged; Naphthalenes - adverse effects; Naphthalenes - therapeutic use; Original; Pharmacology. Drug treatments; Practice Guidelines as Topic; Renal Dialysis; Treatment Outcome; Vitamin D - therapeutic use; Endocrinopathy; Human; Kidney disease; Agonist; Urinary system disease; Calcimimetic agent; Hemodialysis; Low dose; Peptide hormone; haemodialysis; Antihormone; Extrarenal dialysis; Treatment; Vitamin D; Parathyroid hormone; Parathyroid diseases; Hydrochlorides; Analog; Renal failure; Paricalcitol; Cinacalcet; cinacalcet hydrochloride; Comparative study; Hyperparathyroidism